Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Don Walster who wrote (219)	11/18/1998 11:17:00 AM
From: ADEL 7	Read Replies (1) \| Respond to of 1386

I agree with Ariella. I am a long term investor in PARS and have a large number of shares but I have to question the job of pars management: 1- No partner for Alrex till now and none for the near future. 2-We as investors though that we will have a partner for phase III trial for HU-211 in Q1 of 1999 to discover that it may not happen till Q2 and who knows if it is true.May be Q3or Q4 3-Bad deal with CC 4-Bad deal with BOL The bottom line PARS has a good science and needs a good management Everything is so difficult to get it done by the current management. We as investors have to wait and wait because the management are so great and are trying to get the best deal. The management has never gotten for us any good deal so far. Like Ariella, I'll keep my eyes open for my investment. Adel

To: Don Walster who wrote (219)	11/18/1998 2:02:00 PM
From: Ariella	Respond to of 1386

Don -- chance of Pharmos "going broke" seems absolutely zero to me. The company has enough momentum in current drugs on market and LE-T expected at end of 1999 that this is not an issue. What I'm watching is the risk associated with the stretching out of plans -- a longer timetable perhaps than formerly thought. If that happens (and I'm not saying emphatically that it will). the company will stay in business in future the same way as in the past-- it will issue shares, albeit at a slower pace than was true in the past. I have no way to predict when the partnership will be made for HU-211 and it doesn't look to me now as if the ramp up of Alrex/Lotemax will happen speedily enough to cover cash burn on its own by Q3 1999 as I had thought possible before. The HU-211 deal is an extremely critical one for the company, one that shouldn't be rushed just to bring in cash because we're going to have to live with it for a long time. My bet, therefore, is that the company will end up going through with the plan to sell an additional 3 million shares. I hope that will be the last share dilution we get. -Ariella